ANIK — Anika Therapeutics, Inc.

Summary of Anika's Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $29.6 million, up 13% year-over-year.
• Commercial Channel Revenue: Grew 12% to $12.6 million, driven by strong international performance and the Integrity product line.
• International OA Pain Management Revenue: Nearly $9 million, reflecting 9% growth.
• OEM Channel Revenue: $17 million, a 14% increase year-over-year, influenced by favorable order timing.
• Gross Margin: Improved to 64%, up from 56% in Q1 2025, due to higher productivity and lean manufacturing initiatives.
• Adjusted EBITDA: Increased to $4.3 million, reflecting strong gross margin expansion.
• Cash Position: Ended the quarter with $41 million in cash and no debt.

2. Strategic Updates and Business Highlights

• Revenue Growth: The company is focused on accelerating sustainable revenue growth, particularly through the Integrity product, which saw a 35% increase in U.S. procedures year-over-year.
• Product Development: Advancements in the hyaluronic acid-based innovation pipeline, including ongoing reviews for Hyalofast and progress on CINGAL's bioequivalence study.
• Operational Improvements: Enhanced operational discipline and execution have led to improved gross margins and reduced nonstandard work.
• Surgeon Training: Anika is actively training surgeons to increase adoption of Integrity, aiming to expand its market share significantly.

3. Forward Guidance and Outlook

• Full Year Revenue Guidance: Maintained at $114 million to $122.5 million, representing 1% to 9% growth.
• Commercial Channel Growth: Expected to grow 10% to 20%, driven by Integrity and international OA pain management.
• OEM Channel Outlook: Projected to be flat to down approximately 5% year-over-year.
• Adjusted EBITDA Guidance: Expected to be 5% to 10% of revenue, supported by operational improvements and cost reduction actions.

4. Bad News, Challenges, or Points of Concern

• OEM Channel Variability: Revenue in the OEM channel is subject to fluctuations based on customer ordering patterns, which could impact future quarters.
• Market Penetration: Despite strong growth in Integrity, only 8% of rotator cuff procedures currently utilize augmentation, indicating a significant opportunity but also a challenge in changing surgeon habits.
• Cost Pressures: Increased R&D expenses reflect ongoing investments, which could pressure profitability if not managed effectively.

5. Notable Q&A Insights

• Gross Margin Projections: Management indicated that while Q1 gross margins were strong, they may not sustain at the same level throughout 2026, suggesting a potential normalization.
• Surgeon Training Targets: Anika has internal targets for training new surgeons on Integrity, but specifics were not disclosed.
• Capital Allocation Post-Repurchase: With $40 million in cash, the company is focused on operational investments and supporting the U.S. regenerative commercial channel, alongside share repurchase considerations.
• Regulatory Timelines: The timeline for Hyalofast's FDA review remains intact, with expectations for a response in the coming months, and the company is preparing for a potential launch.

This summary encapsulates Anika's financial performance, strategic initiatives, and outlook while highlighting both opportunities and challenges facing the company.